15,006 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Jane Street Group LLC

Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,006 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.06% of Eton Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ETON. Parkman Healthcare Partners LLC raised its position in Eton Pharmaceuticals by 2.8% during the third quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after purchasing an additional 7,029 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $54,000. Wasatch Advisors LP purchased a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $1,431,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares during the last quarter. Finally, Aristides Capital LLC purchased a new stake in Eton Pharmaceuticals in the second quarter worth approximately $658,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $13.42 on Wednesday. The company has a market capitalization of $349.60 million, a price-to-earnings ratio of -61.00 and a beta of 1.38. Eton Pharmaceuticals, Inc. has a one year low of $3.03 and a one year high of $15.00. The company’s 50-day moving average is $11.85 and its 200 day moving average is $7.55.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. B. Riley initiated coverage on Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, HC Wainwright boosted their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, January 6th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.